Four items on microneedle patches for vaccine administration

Friday, 7th of December 2018 Print

Four items on microneedle patches for vaccine administration

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.

Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, Pewin W, Frew PM, Yu T, Thornburg NJ, Kabbani S, Lai L, Vassilieva EV, Skountzou I, Compans RW, Mulligan MJ, Prausnitz MR; TIV-MNP 2015 Study Group.

Lancet. 2017 Aug 12;390(10095):649-658.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30575-5/fulltext

 

 

Long-term stability of influenza vaccine in a dissolving microneedle patch.

Mistilis MJ, Joyce JC, Esser ES, Skountzou I, Compans RW, Bommarius AS, Prausnitz MR.

Drug Deliv Transl Res. 2017 Apr;7(2):195-205.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003766/

.

 

Microneedle patches for vaccination in developing countries.

Arya J, Prausnitz MR.

J Control Release. 2016 Oct 28;240:135-141.

https://www.ncbi.nlm.nih.gov/pubmed/26603347

 

 

A microneedle patch containing measles vaccine is immunogenic in non-human primates.

Edens C, Collins ML, Goodson JL, Rota PA, Prausnitz MR.

Vaccine. 2015 Sep 8;33(37):4712-8.

https://www.ncbi.nlm.nih.gov/pubmed/25770786

.

24377545